PRA International Announces Collaboration with Frontage Laboratories
News Dec 05, 2008
PRA International has announced a collaborative agreement with Frontage Laboratories Inc. This partnership enables PRA Early Development Services’ US Clinical Pharmacology Center (PRA EDS US CPC) to now offer a full complement of analytical lab testing services to its existing Phase I – IV clinical trial services in North America.
PRA’s 80-bed Lenexa clinical facility near Kansas City, Missouri, runs a multitude of Phase I and Phase IIa studies each year, with a particular focus on first in human studies and other complex PK studies.
By meaningfully broadening its bioanalytical service portfolio, PRA now offers Pharma and Biotech sponsors and other CROs the ability to align the clinical and laboratory processes. It already operates a comparable full-service offering in Europe.
Although PRA conducts clinical trials across a broad spectrum of therapeutic areas, it has a special emphasis in the areas of oncology, central nervous system, allergy/respiratory, cardiovascular disorders and infectious diseases.
Frontage Laboratories Inc. is fully compliant with cGMP/GLP regulations and under this new collaboration will offer specialized bioanalytical services via PRA. The new collaboration also offers pharmacokinetic & biostatistical consultancy and data support.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
The heart is the first organ to develop in the womb and the first cause of concern for many parents. Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby."We can try to rebuild the shape of the early development heart in the lab," said Professor Zhen Ma. "It mimics the very early stage, during the embryo genesis - how the heart was formed."READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018